admin – Page 3670 – Get News Story

Kruger & Hodges Announces the Personal Growth Through Leadership Scholarship

Kruger & Hodges Offers $2,500 to Empower Leaders Through Personal Growth Scholarship

Hamilton, OH – April 2, 2025 – Kruger & Hodges Attorneys At Law, widely known as “The Hometown Lawyers,” is pleased to introduce its 2025 “Personal Growth Through Leadership” scholarship. This $2,500 scholarship is designed to support one deserving student who has demonstrated exceptional leadership skills and is currently enrolled in or admitted to an accredited college, university, or graduate school.

This initiative reflects Kruger & Hodges Attorneys At Law’s dedication to fostering personal growth and leadership among students across the country. The scholarship celebrates students who have taken on leadership roles in their lives, overcome challenges, and learned valuable lessons that have shaped their educational and professional goals. Whether serving as a team captain, leading a community service project, or mentoring peers, students from all fields of study are encouraged to apply.

“Leadership is about making an impact, not just holding a title. With this scholarship, we aim to empower students to reflect on their growth, embrace their leadership potential, and use those experiences to pave the way for a brighter future,” said a representative from Kruger & Hodges Attorneys At Law.

To qualify, applicants must submit a 2-3 minute video sharing their leadership journey. The video should focus on the following prompts:

• What challenges did you face, and how did you overcome them?

• What valuable lessons did you learn from this experience?

• How did this leadership role influence your academic and career aspirations?

Applicants are encouraged to treat these questions as a guide while also sharing additional insights into their personal growth. Videos must be uploaded to YouTube as unlisted, and the link should be submitted using the online scholarship application form.

The “Personal Growth Through Leadership” scholarship will help cover tuition, room and board, or other education-related expenses. Students are encouraged to highlight the transformative impact of their leadership roles and demonstrate how they intend to use these experiences to contribute to their communities.

To be considered for the scholarship, students must meet the following criteria:

• Be in good academic standing.

• Be enrolled in or admitted to an accredited college, university, or graduate school.

• Be a U.S. citizen or authorized to attend school or work in the United States.

• Submit a video on the designated topic using the scholarship application form.

The application deadline is October 15, 2025, and the winner will be announced during the fall of 2025. Kruger & Hodges Attorneys At Law hopes to inspire the next generation of leaders and is eager to review creative and compelling applications from students nationwide.

About Kruger & Hodges Attorneys At Law

Kruger & Hodges Attorneys At Law, “The Hometown Lawyers,” is a trusted law firm serving Hamilton, Middletown, Eaton, Wilmington, Washington Court House, Circleville, Urbana, and surrounding communities in Ohio. The firm focuses on personal injury and criminal defense, offering clients compassionate and personalized legal representation. With a commitment to justice and client advocacy, Kruger & Hodges Attorneys At Law ensures that every client has direct access to their attorney and receives dedicated support throughout their case.

In addition to providing exceptional legal services, Kruger & Hodges Attorneys At Law prioritizes giving back to the communities they serve. The “Personal Growth Through Leadership” scholarship is a reflection of the firm’s belief in the power of education and leadership to create lasting change. By supporting students in their academic endeavors, Kruger & Hodges Attorneys At Law demonstrates its commitment to building a brighter future for all.

For more information about the scholarship or to access the application form, visit the Kruger & Hodges website.

Media Contact
Company Name: Kruger & Hodges Attorneys At Law
Contact Person: Fabrizio Mundaca
Email: Send Email
State: Ohio
Country: United States
Website: https://thehometownlawyers.com/

anynines Expands Open-Source Klutch Project as a Multi-Cloud Data Service Integration Platform

Leading cloud computing and automation provider enhances Klutch to simplify data service integration across on-premises and public cloud environments, with new integrations for Amazon S3 and RDS, advanced networking, and automation backends

anynines, a key sponsor and core maintainer of the open-source Klutch project, is expanding Klutch as a comprehensive data service integration platform that supports both on-premises and public cloud environments. Klutch provides a unified control plane for managing diverse data services in Kubernetes, enabling organizations to seamlessly integrate cloud provider-managed services alongside their own infrastructure.

anynines is introducing initial integrations with Amazon Web Services (AWS), starting with Amazon S3 for storage and Amazon RDS for database management. These integrations serve as the foundation for a broader strategy to support multi-cloud environments, including services from Azure, Google Cloud Platform (GCP), and other infrastructure providers.

Klutch: A Flexible and Scalable Data Service Integration Platform

Klutch simplifies database and data service management across Kubernetes application clusters, enabling application developers with on-demand self-service and providing platform teams with centralized governance. As part of anynines’ broader mission, Klutch extends its capabilities to seamlessly integrate vendor-managed services from cloud providers, making it easier for organizations to standardize and scale their database operations without vendor lock-in.

“Our vision for Klutch goes beyond any single cloud provider,” said Julian Fischer, CEO of anynines. “We are building a platform that enables organizations to integrate and manage data services across on-premises infrastructure and multiple public cloud environments. Starting with AWS services like S3 and RDS, we are laying the foundation for expanding support to additional services from Azure, GCP, and beyond.”

Expanding Klutch’s Multi-Cloud Capabilities

While Amazon S3 and RDS are the first cloud services to be integrated, Klutch is designed to support an evolving ecosystem of automation backends. This approach ensures enterprises can optimize their use of vendor-provided cloud services while maintaining centralized automation and governance within Kubernetes.

Klutch simplifies the management of databases and other data services across Kubernetes application clusters, enabling application developers with on-demand self-service and providing platform teams with centralized control and governance. By extending Klutch with new advanced features, anynines strengthens its core data service offerings, ensuring secure, scalable, and efficient database operations in dynamic cloud-native landscapes.

“Our advanced features for Klutch are designed to meet the evolving demands of enterprises seeking robust, secure, and scalable data service management across diverse environments,” said Julian Fischer, CEO of anynines. “As core maintainers of the Klutch project, we are uniquely positioned to deliver the deep expertise and advanced capabilities required to maximize the potential of Klutch deployments.”

Expanding Klutch’s Role as a Multi-Cloud Connector

Klutch is a foundational framework designed to help organizations with many Kubernetes application clusters seamlessly consume vendor-provided infrastructure services from AWS, Azure, and Google Cloud Platform (GCP). As a consistent control plane for database and data service automation, Klutch enables organizations to integrate and manage cloud provider services efficiently within their Kubernetes environments.

By providing a flexible integration framework, Klutch allows enterprises to orchestrate, govern, and automate data services in both private and public clouds, ensuring a consistent and scalable data management experience.

Key Enhancements to Klutch by anynines

Amazon S3 Integration: Direct integration with S3 to streamline data backups, storage, and recovery processes, ensuring secure and efficient handling of large datasets.
Amazon RDS Integration (In Development): Enabling organizations to extend Klutch’s control plane to manage Amazon RDS instances directly, further simplifying cloud database operations.
Multi-Cloud Support: Future expansions will include connectors for Azure Database for PostgreSQL, Azure Blob Storage, Google Cloud SQL, Google Cloud Storage, and additional services to standardize Kubernetes-based infrastructure automation across cloud providers.
Expert Support from Core Maintainers: Direct access to the Klutch core development team for architectural guidance, performance optimization, and advisory services.
Advanced Access & Security Controls: Security measures, including granular role-based access control (RBAC), comprehensive audit trails, policy enforcement, and detailed usage tracking.
Seamless Infrastructure & Multi-Cloud Integration: Support for custom automation backends, multi-cloud deployments across major public and private cloud platforms, and advanced networking configurations.
Network Connector: A dedicated networking connector that ensures secure, scalable application-to-data-service connectivity by handling infrastructure-specific networking details. The network connector provides flexibility for organizations implementing cloud-native, Kubernetes-native, or custom on-prem solutions.
Simplified Service Discovery & Cross-Cluster Connectivity: Automatic cluster binding for easy service discovery, policy-driven access management, and certificate lifecycle management to ensure encrypted communications.

Custom-Built Data Services & Automation Backends

anynines specializes in data service automation and provides integrations with Klutch for PostgreSQL, RabbitMQ, MongoDB, MariaDB, Prometheus, Valkey, and more. These solutions form the foundation of enterprise-grade Database-as-a-Service (DBaaS) offerings, ensuring reliability, automatic scaling, disaster recovery, and continuous updates without the complexity of infrastructure management. By reducing operational burdens, these services empower technical teams to focus on innovation and accelerate digital transformation.

Beyond its existing portfolio of data services as automation backends, anynines also offers custom-built automation backends tailored to customer needs. Currently, anynines is actively developing integration with Amazon RDS, but this is only the beginning. Klutch’s vision is to act as a multi-cloud automation enabler, allowing enterprises to connect seamlessly to the most popular cloud infrastructure services across AWS, Azure, and GCP. Future iterations will focus on expanding automation capabilities to cover a broader range of storage, networking, and managed database services from leading cloud providers.

“Klutch is the missing piece in the puzzle of Kubernetes-native data service automation,” Fischer said. “By enabling seamless integration with cloud-provider-managed services while maintaining control over on-premises data services, organizations can standardize and automate their operations with greater confidence.”

Join the Klutch Community & Explore anynines’ Data Services

As the Klutch project continues to grow, anynines and the open-source project are actively seeking additional sponsors, partners, and contributors to help shape the future of database and data service management in Kubernetes environments.

Organizations interested in exploring anynines’ professional services for Klutch or their data service automation solutions can schedule a consultation, request a demonstration, or plan a technical assessment and proof of concept with anynines’ expert team.

For more information about anynines’ features for Klutch, visit anynines.com/klutch. To learn more about Klutch’s open-source features, visit klutch.io.

About anynines

anynines is a cloud computing and automation company dedicated to empowering organizations and enterprises with innovative tools for operational efficiency, developer productivity, and compliance in on-premise and multi-cloud environments. For more than 15 years, the Germany-based company has specialized in building and operating large-scale application development platforms and data services for enterprises on their digital transformation journey. Learn more at anynines.com.

Media Contact
Company Name: Anynines GmbH
Contact Person: McKinzie Brocail
Email: Send Email
Phone: +49 681 1095 409
Address:Science Park 2
City: Saarbrücken, 66123
Country: Germany
Website: https://www.anynines.com

AI Paradox in QA: Twice as Many Testers Fear Job Loss, But Adoption Keeps Climbing

Source: Katalon, 2025 State of Software Quality Report

Katalon’s 2025 State of Software Quality Report reveals insights from 1,500 QA professionals worldwide

ATLANTA, GA, USA – Despite fears of job loss, Quality Assurance (QA) professionals are leaning into AI faster than ever, according to Katalon’s newly released 2025 State of Software Quality Report. The report reveals that testers using AI tools are twice as likely to fear being replaced by them, a paradox that underscores the profession’s evolving relationship with automation. Yet those with stronger AI fluency aren’t just adapting — they’re testing faster, leveling up their skills, and reclaiming joy in the work that once burned them out.

That shift is fueled by both urgency and intent. As AI reshapes expectations, 82% of QA professionals say AI skills will be critical in the next 3 to 5 years, and teams are already adapting. The report finds that those with higher AI fluency excel not just at using new tools, but in test planning, problem-solving, and applying AI concepts in real-world scenarios.

To close the skills gap, 67% of teams are investing in continuous learning, while 53% are adopting AI-driven testing practices to stay ahead. And for the most advanced teams, QA is no longer just a safeguard, it’s a business enabler. In fact, 77% of respondents say aligning QA with business goals has helped improve customer retention.

Katalon’s 2025 State of Software Quality Report surveyed over 1500 quality professionals, from engineers to senior executives, across North America, Europe, and Asia-Pacific. The report explores the challenges, capabilities, and innovations shaping today’s testing landscape — and how QA teams are evolving from execution-focused roles to strategic drivers of business value.

“The shift toward AI-powered testing isn’t just accelerating — it’s inevitable. This year’s report validates what we’ve long believed: QA professionals, the unsung heroes of software innovation, are navigating intense pressure to move faster without compromising quality, and their impact is finally being recognized, with 48% of organizations now viewing QA as a competitive advantage. Looking ahead, the future of quality will belong to teams who can combine AI fluency with human insight to lead testing into a smarter, more adaptive era.” – Vu Lam, CEO of Katalon

The key highlights of Katalon’s 2025 State of Software Quality Report are:

AI Integration with Human Expertise: Testers who blend AI, automation, and manual testing skills with critical thinking, the new generation of hybrid testers—are leading the next wave of innovation in software quality. According to the report, high-maturity QA teams that leverage these hybrid testers are 1.3 times more likely to adopt AI-augmented test optimization and 1.8 times more likely to implement intelligent test maintenance practices like self-healing tests, compared to lower-maturity teams.

The Happiness Edge: Happier QA pros aren’t just more satisfied, they’re more effective. According to the report, they’re 1.4 times more likely to implement advanced automation solutions (46% vs. 34%) and 1.4 times more likely to say AI has improved efficiency and automation in their roles (71% vs. 52%). As organizations modernize, these findings reveal a clear connection between job satisfaction and innovation in software quality.
AI and The Future of QA: AI-driven testing is gaining momentum, with 61% of QA teams adopting it to automate repetitive tasks and free up time for more strategic work. Forward-looking teams are embracing advanced automation tools, augmented with AI, with the potential to make testing more adaptive, efficient, and intelligent. Beyond AI, they’re also investing in performance and load testing tools (34%) and test management platforms (30%) to further optimize workflows and scale quality with confidence.
Redefine quality with AI: The research shows that high-performing teams are modernizing on three critical fronts: 61% are adopting AI-driven tools, 51% are using modern development practices, and 40% are investing in continuous testing. Together, these shifts are accelerating release cycles while preserving what matters most: trust, reliability, and quality at scale.

Resources

Download the full report – katalon.com/SoSQR2025
Save your seat for the April 24 virtual summit – katalon.com/webinars/quality-horizon Join Katalon, industry experts, and QA leaders to discuss key findings from the report and what’s next for AI in testing.
Explore the future of software quality – katalon.com

About Katalon

Katalon is the category leader in AI-augmented software testing, empowering hybrid testers — those blending manual, automation, and AI skills, to deliver exceptional digital experiences. Trusted by more than 30,000 QA and DevOps teams across 80+ countries, Katalon has been named a G2 Leader in software testing for 11 consecutive quarters. Founded in 2016 and headquartered in Atlanta, Katalon helps teams accelerate software delivery and elevate quality through a powerful, integrated test automation platform, empowering them to release with speed and confidence.

Media Contact
Company Name: Katalon
Contact Person: (Ms) Nhung (Rosie) Nguyen
Email: Send Email
Phone: 39689137
Country: United States
Website: https://www.katalon.com

District Speech and Language Therapy in Washington, DC Announces New Website Launch

District Speech and Language Therapy (District Speech), a premier provider of speech therapy in Washington, DC, is excited to announce the launch of its newly redesigned website. The revamped site is now live and offers an enhanced user experience, reflecting the clinic’s commitment to providing accessible, comprehensive speech therapy services to the local community.

The newly launched site features a modern, streamlined design with user-friendly navigation. Visitors to the site will find a wealth of information about the services District Speech offers, including speech therapy children and adults, in clinic and through “virtual” speech therapy, sometimes called speech teletherapy. The updated website is designed to improve accessibility and provide valuable resources for current and prospective clients.

“People who seek speech therapy come from all walks of life,” says the website’s updated home page. “Maybe you have an issue with stuttering. Maybe you’re a parent whose child isn’t using words yet, has a cleft palate, a lisp secondary to tongue thrust, reading difficulties or another speech concern. Whatever it is that’s holding you back, our team of therapists can help.”

The website’s responsive design ensures it works seamlessly across all devices, from desktop computers to mobile phones, allowing clients to access important information whenever they need it. Whether individuals are looking for therapy for themselves or their children, the updated website simplifies the process of connecting with District Speech’s team of experienced therapists.

Along with the refreshed website comes a continued commitment to speech therapy education via the clinic’s speech therapy blog. Celebrating its ten year anniversary this year, the District Speech blog provides a wealth of information on the field of speech therapy for people with speech and language disorders, and their loved ones.

District Speech and Language Therapy has built a reputation for its compassionate approach to speech and language therapy. By incorporating the latest research-based techniques and personalized treatment plans, District Speech has helped hundreds of clients improve their communication skills and achieve their personal goals.

Those interested in District Speech’s services are encouraged to visit their website, linked above, or by visiting their downtown DC speech therapy clinic.

Media Contact
Company Name: District Speech & Language Therapy
Contact Person: Jennifer Branchini, MA, CCC-SLP
Email: Send Email
Phone: 1 (202) 579-4448
Address:1300 I St NW Suite 400 E
City: Washington
State: DC 20005
Country: United States
Website: https://districtspeech.com/

ACO features in UNESCO World Engineering Day 2025 campaign

ACO, as a leader in water technology, has been selected as an official partner for UNESCO World Engineering Day for Sustainable Development (WED) 2025, which was launched at UNESCO Headquarters in Paris on 4 March 2025.

London, UK – 2 Apr, 2025 – An International Day proclaimed by the UNESCO General Conference and open to everyone, WED is jointly operated by UNESCO and the World Federation for Engineering Organisations (WFEO), which spans some 100 countries and represents more than 30 million engineers.

The launch in Paris marks the start of a year-long campaign of events, films, articles and news, highlighting the achievements of engineers and engineering around the world, and promoting engineering as a career.

Produced by the SJH Group – the official media partner and broadcaster for WED – all campaign content, which includes a multimedia hub dedicated to ACO, is hosted on the WED website at www.worldengineeringday.net

As an official partner, ACO’s insights and expertise will form an integral part of the 12-month campaign, which provides a springboard for governments, UN-associated organisations, policymakers, educators and leaders in the public and private sectors to raise awareness of the importance of engineering.

The WED campaign has an estimated global reach of more than 100 million individuals, and this year’s theme of “Shaping our sustainable future through engineering” focuses on the essential role that engineering has to play in achieving the UN’s 17 Sustainable Development Goals (SDGs).

Hans-Julius and Iver Ahlmann, Chairmen of the ACO Group, say:

“Technology will make a decisive contribution to solving the climate crisis. We are innovation leaders in the field of Water-Tech, and that is what drives us.”

Addressing the significance of WED, Mustafa Shehu, President of the WFEO, says:

“World Engineering Day 2025 is all about putting engineering in the global spotlight, showing how engineers are leading the way in the effort to meet the UN’s Sustainable Development Goal targets, and inspiring the next generation to find out more about what a career in engineering has to offer.”

Jacques de Mereuil, Executive Director of the WFEO, says:

“We’re thrilled to be involved in launching this important international celebration and campaign at UNESCO’s global headquarters in Paris, and delighted to have ACO involved, as an authority in water technology.”

To view ACO’s WED content, go to: worldengineeringday.net/partner-stories/aco/

Media Contact
Company Name: WFEO
Contact Person: Media Relations
Email: Send Email
Country: United Kingdom
Website: worldengineeringday.net/partner-stories/aco/

Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron

The Key Follicular Lymphoma Companies in the market include – Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others.

FelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Follicular Lymphoma Market Forecast

Some of the key facts of the Follicular Lymphoma Market Report:

The Follicular Lymphoma market size was valued ~USD 1,082 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In February 2025, Genmab A/S (Nasdaq: GMAB) announced that the Japan Ministry of Health, Labour, and Welfare has approved EPKINLY® (epcoritamab) for treating patients with relapsed or refractory follicular lymphoma (FL; Grades 1 to 3A) who have undergone two or more prior treatments. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved in Japan for both relapsed or refractory FL and large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma, after two or more prior therapies.
In February 2025, Regeneron Pharmaceuticals announced the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company expects a decision from the FDA in the second half of 2025.
In January 2025, CRISPR Therapeutics announced plans to collaborate with regulatory authorities to determine the next steps for CTX112 in B-cell malignancies, with an update anticipated by mid-2025.
In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies.
In 2024, approximately 35,000 cases of follicular lymphoma were diagnosed across the 7MM.
In 2024, the United States generated around USD 1,082 million in revenue.
In 2024, Germany represented the largest market size among the EU4 and the UK, with an estimated value of around USD 108 million.
In 2024, Spain had the smallest market size among the EU4 and the UK, with an estimated value of around USD 61 million.
Follicular lymphoma is an indolent variety of non-Hodgkin’s lymphoma (NHL) originating from germinal center B cells. Follicular lymphoma is one of the most prevalent forms of indolent B cell NHL. It has a long disease course due to the chronic incurable nature of the disease in the majority of patients.
In 2024, the United States had the highest number of Follicular Lymphoma cases among the 7MM, with approximately 17,000 cases. This number is expected to rise by 2034.
In 2024, the 60–80 age group had the highest incidence of follicular lymphoma, with around 9,000 cases, followed by the 40–59 age group with approximately 4,000 cases.
In 2024, stage IV follicular lymphoma cases accounted for approximately 34% of all cases.
In 2024, the incidence of follicular lymphoma in the EU4 and the UK was approximately 14,000, with Germany reporting the highest number of cases.
Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
The Follicular Lymphoma epidemiology based on risk analyzed that low risk, intermediate risk and high risk patients contribute to 20%, 53% and 27% of all FL cases, respectively
The Follicular Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics.

Follicular Lymphoma Overview

Follicular Lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), which is a cancer of the lymphatic system. It originates from B lymphocytes (B cells), a type of white blood cell that plays a crucial role in the immune system. Follicular Lymphoma is characterized by the formation of abnormal, usually slow-growing, lymphoid follicles in the lymph nodes.

Get a Free sample for the Follicular Lymphoma Market Report:

https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights

Follicular Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Follicular Lymphoma Epidemiology Segmentation:

The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Follicular Lymphoma
Prevalent Cases of Follicular Lymphoma by severity
Gender-specific Prevalence of Follicular Lymphoma
Diagnosed Cases of Episodic and Chronic Follicular Lymphoma

Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ Follicular Lymphoma Epidemiology Forecast

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Follicular Lymphoma Therapies and Key Companies

LUNSUMIO (mosunetuzumab): Roche
BRUKINSA (zanubrutinib): BeiGene
YESCARTA: Kite Pharma
MONJUVI (tafasitamab): Incyte Corporation
AZD0486: AstraZeneca
Abexinostat: Xynomic Pharmaceuticals
ME-401: MEI Pharma
Tisagenlecleucel: Novartis
Parsaclisib (IBI376): Innovent Biologics
Odronextamab: Regeneron
Mosunetuzumab: Genetech
Abexinostat: Xynomic Pharma
Rituximab IV: Roche
Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche
Enzastaurin: Eli Lilly and Company
Loncastuximab tesirine: ADC Therapeutics S.A
Zanubrutinib: BeiGene
Bendamustine: Cephalon
Tazemetostat: Epizyme, Inc.
ibrutinib: Pharmacyclics LLC.
Obatoclax mesylate: Gemin X
Ibrutinib: AbbVie
IXAZOMIB: Millennium Pharma

To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Clinical Trials and Therapeutic Assessment

Follicular Lymphoma Market Strengths

Follicular lymphoma market has a diverse pipeline,with emergence of novel classes such as bi-specificantibodies, cancer vaccine and allogenic CAR-Ts.

Follicular Lymphoma Market Opportunities

R-CHOP continues to be the gold standard of caredespite other therapies or combinations that have tried to advance the treatment paradigm

Scope of the Follicular Lymphoma Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Follicular Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Follicular Lymphoma Market Access and Reimbursement

Discover more about therapies set to grab major Follicular Lymphoma market share @ Follicular Lymphoma Treatment Landscape

Table of Contents

1. Follicular Lymphoma Market Report Introduction

2. Executive Summary for Follicular Lymphoma

3. SWOT analysis of Follicular Lymphoma

4. Follicular Lymphoma Patient Share (%) Overview at a Glance

5. Follicular Lymphoma Market Overview at a Glance

6. Follicular Lymphoma Disease Background and Overview

7. Follicular Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Follicular Lymphoma

9. Follicular Lymphoma Current Treatment and Medical Practices

10. Follicular Lymphoma Unmet Needs

11. Follicular Lymphoma Emerging Therapies

12. Follicular Lymphoma Market Outlook

13. Country-Wise Follicular Lymphoma Market Analysis (2020–2034)

14. Follicular Lymphoma Market Access and Reimbursement of Therapies

15. Follicular Lymphoma Market Drivers

16. Follicular Lymphoma Market Barriers

17. Follicular Lymphoma Appendix

18. Follicular Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron

Islands.co Reports Key Travel Trends Shaping the Private Island Market in 2025

Islands.co reports rising interest in eco-friendly, short-term, and Southeast Asian private island escapes as 2025 luxury travel trends take shape.

As private island getaways grow in popularity, Islands.co, a global marketplace for exclusive island rentals and sales, has released new insights revealing the direction luxury travel is taking in 2025. The data, gathered from user behavior across the platform, points to a shift toward sustainability, intentional travel, and a desire for more accessible luxury escapes.

According to Islands.co, travelers are increasingly interested in island properties that offer eco-friendly features, such as off-grid infrastructure and sustainable architecture. The trend reflects a growing awareness of environmental responsibility in the luxury market. Alongside this, demand for short-term private island rentals is climbing, showing that more travelers are looking to enjoy private island experiences without long-term commitments.

Georgio Daher, CEO of Islands.co, believes these patterns are part of a broader change in how people approach high-end travel. “We’re seeing a new kind of luxury emerge — one that’s less about extravagance and more about authenticity, seclusion, and purpose,” said Daher. “Whether it’s a digital detox or a week on a sustainably built island, people are seeking experiences that feel exclusive but also meaningful.”

Search interest in island destinations across Southeast Asia — particularly Thailand, Indonesia, and the Philippines — has also surged in early 2025. These regions offer natural beauty, investment opportunities, and growing availability of rental-ready and undeveloped islands.

Additionally, Islands.co has seen increased activity from users seeking completely undeveloped islands, especially among investors looking for long-term development opportunities or future boutique resort projects.

These emerging trends point to a market that values both luxury and responsibility. As private island travel continues to evolve, Islands.co remains focused on connecting travelers and investors with properties that align with these changing expectations.

About Islands.co:

Islands.co is a global marketplace for private island rentals and sales, offering a curated selection of exclusive listings for travelers, buyers, and investors seeking extraordinary destinations.

Media Contact
Company Name: Islands Online LTD
Email: Send Email
Country: United Kingdom
Website: https://islands.co

Beijing Times Enhances Mobile Experience with Fresh Design Updates

Beijing Times has launched minor design updates to improve the mobile reading experience, including better layout and readability. The platform remains committed to accessible, high-quality journalism for a global audience.

Beijing Times, the global digital news platform owned by Daher Media, has rolled out a series of light design improvements aimed at enhancing the reading experience for its growing mobile audience. The updates, which include refined typography, cleaner layouts, and faster page loading, are part of the platform’s ongoing effort to provide a seamless and enjoyable experience across all devices.

As mobile readership continues to rise, Beijing Times remains committed to adapting its user interface to meet evolving reader preferences. The refreshed design ensures articles are easier to read, visually appealing, and more accessible for users navigating the site on smartphones and tablets.

“We’re always listening to our readers and looking for ways to improve how they engage with our content,” said Georgio Daher, CEO of Daher Media. “These updates are small but meaningful steps toward making Beijing Times more user-friendly and enjoyable for our global audience.”

The improvements come as part of a broader plan to continuously enhance the platform’s functionality, while maintaining its core identity as a trusted source of non-political, globally relevant journalism.

To explore the updated mobile experience, visit www.beijingtimes.com.

About Beijing Times:

Beijing Times is a global digital news platform delivering unbiased coverage of business, lifestyle, culture, and world affairs. Known for clarity and neutrality, it serves readers seeking factual, non-political journalism.

About Daher Media:

Daher Media is a London-based public relations and communications firm offering high-impact strategies for global brands and public figures. Known for innovation, integrity, and influence, it helps clients craft compelling narratives in a fast-moving world.

Media Contact
Company Name: Beijing Times
Contact Person: Team
Email: Send Email
Country: United Kingdom
Website: www.beijingtimes.com

Beijing Times Rolls Out Mobile Design Enhancements for Smoother Reader Experience

Beijing Times has introduced mobile-friendly design updates to improve readability and user experience, reaffirming its focus on accessible, high-quality journalism for modern readers.

London, UK – Beijing Times, the global digital news outlet operated by Daher Media, has introduced a series of small but impactful design upgrades to improve mobile accessibility for its growing international audience. These updates include improved text readability, cleaner layouts, and faster page load speeds, making articles more comfortable to consume on the go.

With mobile readership steadily increasing, Beijing Times took a reader-first approach to fine-tune the platform’s user interface without altering its core identity. The aim is to create a distraction-free, fluid experience that encourages deeper engagement with stories on culture, business, and global affairs.

The changes reflect Beijing Times’ ongoing commitment to delivering high-quality, neutral journalism while continuously adapting to the needs of today’s digital readers.

Readers can explore the new design now at www.beijingtimes.com.

About Beijing Times:

Beijing Times is a global digital news platform focused on delivering unbiased, non-political reporting on business, lifestyle, culture, and international developments. It serves readers who value clarity, credibility, and global perspective.

About Daher Media:

Daher Media is a London-based communications and PR firm that works with global brands, institutions, and media platforms. Known for its strategic storytelling and innovative approach, Daher Media helps clients amplify their message with impact and integrity.

Media Contact
Company Name: Beijing Times
Contact Person: Team
Email: Send Email
Country: United Kingdom
Website: www.beijingtimes.com

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

Stem cells have a unique ability—they can transform into different types of cells, making them a game-changer in regenerative medicine. From repairing heart tissue after a heart attack to potentially reversing neurodegenerative diseases like Alzheimer’s, the possibilities are vast.

While their potential has been known for years, challenges such as immune rejection and difficulty in controlling cell differentiation have slowed progress. However, advances in DNA and RNA research have given scientists better control over the process, opening the door to real-world treatments.

The stem cell industry is now shifting from theoretical breakthroughs to tangible medical applications. In 2024, the global stem cell market was valued at $15.1 billion and is projected to grow at an annual rate of 11.41% through 2030. This surge is driven by increased research, growing demand for stem cell banking, and major strides in precision medicine.

Now, let’s take a closer look at a few stocks making waves in this sector.

ADIA Nutrition Inc. (OTC Pink: ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space. The company operates through two main divisions: a nutritional supplement business and its medical division, Adia Med, which is focused on advanced stem cell therapies. ADIA’s recent announcements and strong growth trajectory suggest the company is positioning itself as a leader in this high-potential sector.

One of the company’s standout moves is its commitment to expanding stem cell treatments across the United States. In January 2025, ADIA opened its flagship clinic in Winter Park, Florida, where it already offers treatments using umbilical cord stem cells (UCB-SC) to address conditions like Multiple Sclerosis, orthopedic injuries, and joint pain. The clinic exceeded financial expectations in its first month, covering all startup costs and proving that there is strong demand for its therapies. This success set the stage for further growth, including the opening of satellite locations across the country.

ADIA’s medical division, Adia Med, is also making waves with its decision to offer Therapeutic Plasma Exchange (TPE) at all future full-service clinic locations. TPE, which removes harmful substances from a patient’s blood, is being used to treat a variety of conditions, including Alzheimer’s disease. This is a major move in a rapidly growing field. According to ADIA’s CEO, Larry Powalisz, “Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care.” This technology sets ADIA apart from other players in the field and positions the company to lead in advanced treatment options for patients with neurodegenerative diseases.

Another area where ADIA is taking a leadership role is in the standardization of stem cell treatments. The company is working on setting new quality and safety standards for umbilical cord stem cell use in the United States. With many clinics offering subpar or non-viable stem cells, ADIA is aiming to make sure every patient gets stem cells that are live and effective. As CEO Larry Powalisz stated, “We’re crafting a movement for reliability and excellence.” The company plans to present its standards to the FDA and the Department of Health and Human Services, pushing for nationwide regulations that could transform the entire stem cell industry.

On top of that, ADIA is preparing to expand internationally, as multiple overseas organizations have expressed interest in licensing the company’s treatments. The company is already in the process of reviewing the legal and regulatory steps required to bring its innovative therapies, like its flagship Adia Vita stem cell product, to other markets. ADIA’s international expansion could help it tap into a global market for regenerative medicine, offering the company even more room to grow.

Lastly, ADIA’s asset-light expansion model is another key factor driving its growth. In March 2025, the company opened its first satellite clinic in Tinton Falls, New Jersey, in partnership with Keep Glowing Medical Spa and Dr. Michael Ellis. This shared space partnership allows ADIA to expand quickly without the overhead costs of building new clinics from the ground up. The Tinton Falls location will offer ADIA’s stem cell therapies, including Adia Vita and AdiaLink, to patients seeking advanced treatments for a variety of conditions.

ADIA Nutrition’s combination of strong financial performance, strategic partnerships, and commitment to innovative treatments makes it an exciting stock to watch in the stem cell space. With its focus on quality, expanding treatment options, and international growth, ADIA is positioning itself to be a leader in regenerative medicine. Investors looking for a company with significant growth potential in this booming sector should keep an eye on ADIA as it continues to expand and evolve.

Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that is making strides in developing stem cell therapies for both cancer and autoimmune diseases. The company’s approach is built around induced pluripotent stem cells (iPSCs), which can be used to create cell therapies that are ready to be used right off the shelf. This eliminates some of the challenges of traditional stem cell treatments, which require personalized, patient-specific cells. By creating universal, off-the-shelf therapies, Fate aims to make stem cell treatments more accessible and cost-effective.

One of the most promising candidates in Fate’s pipeline is FT819, a type of CAR T-cell therapy designed to treat autoimmune diseases, particularly systemic lupus erythematosus (SLE). FT819 is especially notable because it doesn’t require the usual chemotherapy conditioning that other CAR T-cell therapies do. Early trials of FT819 have shown strong potential. The first three patients treated with FT819 experienced no dose-limiting toxicities, and one patient even went into remission after the treatment. Bob Valamehr, Fate’s President of Research and Development, expressed his excitement over the results, saying, “We are pleased with the early clinical data, which continues to support the potential for disease transformation.” In addition, the FDA has allowed Fate to expand its trials to include additional autoimmune diseases, which could broaden the market for FT819 significantly.

Fate’s pipeline doesn’t stop with FT819. The company is also advancing other therapies, like FT825 and FT522, which target different types of cancers. FT825 is designed to treat solid tumors, while FT522 focuses on blood cancers. Like FT819, these therapies aim to simplify the treatment process by avoiding the need for chemotherapy conditioning. FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers.

On the financial side, Fate Therapeutics is well-funded, with $307 million in cash and investments at the end of 2024. This gives the company plenty of resources to continue advancing its clinical programs, and the company’s strong partnerships with firms like Ono Pharmaceutical further enhance its growth potential.

With its innovative approach to off-the-shelf stem cell therapies, Fate Therapeutics is positioning itself as a leader in the field. Its therapies for autoimmune diseases and cancer are showing real promise, and with strong financial backing, the company is poised for continued progress in the years ahead.

Mesoblast Limited (NASDAQ: MESO) is a global leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe, life-threatening inflammatory diseases. The company’s therapies leverage its proprietary mesenchymal stromal cell (MSC) technology, which works by releasing anti-inflammatory factors to help modulate the immune system and reduce harmful inflammation. This technology is aimed at addressing conditions like steroid-refractory acute graft-versus-host disease (SR-aGvHD) and chronic heart failure, among others.

Mesoblast’s FDA-approved product, Ryoncil (remestemcel-L), is the first MSC-based therapy to gain approval for the treatment of pediatric patients with SR-aGvHD, a life-threatening condition that occurs after bone marrow transplants. In December 2024, the U.S. FDA approved Ryoncil for use in children as young as two months old, marking a significant milestone for the company. The therapy has demonstrated strong clinical results, with a 70% overall response rate in a Phase 3 trial and a survival rate of 49% at four years for children treated with Ryoncil.

The company is also working on expanding Ryoncil’s applications to other inflammatory diseases, such as adult SR-aGvHD and biologic-resistant inflammatory bowel disease (IBD). Furthermore, Mesoblast is advancing its second key product, Rexlemestrocel-L (Revascor), which is being studied for chronic heart failure and chronic low back pain. These treatments offer promising alternatives to existing therapies by addressing the underlying inflammation that often complicates these diseases.

In terms of growth and financial stability, Mesoblast has been proactive in securing strategic partnerships and expanding its market presence. The company has agreements in key regions such as Japan, Europe, and China. Additionally, it has an extensive intellectual property portfolio, with over 1,000 granted patents covering MSC compositions, manufacturing methods, and therapeutic indications.

Financially, Mesoblast is in a strong position, with a cash balance of $38 million at the end of 2024. The company raised an additional $161 million in a private placement, which bolsters its ability to continue advancing its research and development initiatives. Mesoblast’s CEO, Dr. Silviu Itescu, expressed his enthusiasm about the future, noting, “Our FDA-approved product Ryoncil will be available in the coming weeks to children with SR-aGvHD in need of life-saving therapy.”

Overall, Mesoblast’s strong pipeline of therapies and its leadership in the allogeneic cell medicine space position it as a promising company in the stem cell and regenerative medicine sectors. With its recent FDA approval and expanding commercial partnerships, Mesoblast is set to make a significant impact in treating inflammatory diseases globally.

CRISPR Therapeutics (NASDAQ: CRSP) is a pioneer in gene editing, making history as the first company to bring a CRISPR-based therapy to market. The company’s flagship product, CASGEVY, was approved in multiple countries in late 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)—two serious genetic blood disorders. Since then, patient demand has been strong, with over 50 authorized treatment centers (ATCs) worldwide and more than 50 patients having initiated cell collection by the end of 2024.

Looking ahead, 2025 is shaping up to be a big year for CRISPR Therapeutics. The company is working on next-generation gene-editing programs and expanding into new disease areas like oncology, autoimmune disorders, and cardiovascular diseases. CEO Samarth Kulkarni called 2025 a “milestone-rich year” with major clinical updates expected across the company’s pipeline.

While CASGEVY’s commercial rollout continues, CRISPR Therapeutics is making progress on several other fronts. CTX112 is a next-generation CAR T-cell therapy for blood cancers and autoimmune diseases. Early results showed strong efficacy in lymphoma patients, earning it a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. In cardiovascular disease, CTX310 and CTX320 are experimental therapies targeting cholesterol and lipoprotein(a), a genetic risk factor for heart disease. Clinical updates are expected in the first half of 2025. CTX211 is a gene-edited stem cell therapy for Type 1 diabetes (T1D), designed to free patients from insulin injections without needing long-term immune suppression.

CRISPR Therapeutics ended 2024 with $1.9 billion in cash and investments, giving it a strong financial cushion to fund research and commercialization efforts. The company has also partnered with Vertex Pharmaceuticals on CASGEVY, benefiting from Vertex’s commercial expertise as they roll out the therapy globally.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine